

## Special Issue

# Small Cell Lung Cancer: A New Era Is Beginning?

### Message from the Guest Editors

Small-cell lung cancer (SCLC) is the most aggressive lung cancer: No significant progress has been made in decades, and platinum-based chemotherapy has for a long time represented the standard of care. The improvement in the knowledge of the biology of SCLC has led to the development of new experimental therapies that have shown promising results, including poly [ADP-ribose] polymerase (PARP) inhibitors, anti-Notch ligand Delta-like protein 3 (anti-DLL3), antibody–drug conjugates, and aurora kinase inhibitors. Future challenges are the identification of predictive biomarkers for immunotherapy, the definition of the role of new biological agents, and the improvement of integrated approached for limited disease. This Special Issue will highlight the current state of treatment of limited and extensive SCLC, focusing on biology of SCLC, immune-checkpoint inhibitors, antibody–drug conjugates, PARP inhibitors, and novel cytotoxic chemotherapy and radiotherapy techniques. Prof. Dr. Alessandro Morabito  
Prof. Dr. Christian Rolfo

### Guest Editors

Prof. Dr. Alessandro Morabito

Thoracic Medical Oncology, Istituto Nazionale Tumori IRCCS  
Fondazione Pascale–IRCCS di Napoli, 80131 Naples, Italy

Prof. Dr. Christian Rolfo

Professor of Medicine, Director of Thoracic Medical Oncology Program,  
Director of Early Clinical Trials, Experimental Therapeutics Research  
Program, Marlene and Stewart Greenebaum Comprehensive Cancer  
Center, University of Maryland School of Medicine, Baltimore, MD, USA

### Deadline for manuscript submissions

closed (31 December 2020)



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/50230](https://mdpi.com/si/50230)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)